Top Biotech Companies in Dublin (41)
Opsona Therapeutics is a leading drug development company specialising in the human immune system. Opsona is identifying new ways to prevent and treat autoimmune/inflammatory conditions, cancers and infectious diseases. Opsona's drug discovery & development is focused on the role of Toll-Like Receptors (TLRs) and Inflammasome signalling in human immunology. Since 2004, Opsona has also developed a unique and advanced pipeline...
Eurofins Scientific is an international life sciences company, providing a unique range of analytical testing services to clients across multiple industries, to make life and the environment safer, healthier and more sustainable. From the food you eat to the medicines you rely on, Eurofins works with the biggest companies in the world to ensure the products they supply are safe,...
CropBiome is a company that specialises in the selection and fermentation of plant and soil microbes formulated into products for specific applications. Our core areas of expertise include: - Nutrient efficiency reducing fertilser inputs while maintaining crop yields - Adverse climate conditions, drought stress alleviation. - Reduced disease pressure. - Soil health analysis and conditioning Our services allow crop growers to significantly reduce their costs while...
Since our foundation in Dublin, Ireland in 1990, our mission has been to help our clients to accelerate the development of drugs and devices that save lives and improve quality of life. We do this by delivering best in class information, solutions and performance, with an unyielding focus on quality at all times. We offer a full range of consulting, development...
For over 240 years, Takeda’s propensity to evolve has driven the next generation of innovation, and as a future-focused organization, we’re continuing to drive forward with endurance in our steadfast pursuit to achieve the best outcomes for our patients in a rapidly changing world. We have been preparing for this period of value creation by investing in data, digital and...
Takeda's Top Stability & Growth Strengths
Strong Market Position & Advantage: Takeda is consistently placed among the global top 15–20 by revenue and is a clear category leader in GI/IBD, plasma-derived therapies, and dengue vaccines with broad international authorizations and WHO support. Subcutaneous ENTYVIO and new oncology approvals like FRUZAQLA broaden real‑world use and extend reach.
Profitability: Reported FY2025 operating profit rose 19.3% year over year and EPS nearly doubled despite a slight revenue decline, supported by lower amortization and restructuring expense. Core profitability remained broadly stable as Growth & Launch Products expanded their share.
Future-Ready Strategy: Management is investing through FY2026 to convert a late‑stage pipeline (e.g., oveporexton, rusfertide, zasocitinib) into multiple launches, with Growth & Launch Products prioritized as near‑term engines. A multi‑year transformation and efficiency program targeting significant savings by FY2028 is intended to fund launches and strengthen competitiveness.
Our mission is to transform the lives of people living with rare diseases and devastating conditions through the development and delivery of innovative medicines, as well as through supportive technologies and healthcare services. By continuing to deepen our understanding of rare disease, which began with our pioneering work in complement biology, we are able to innovate and evolve into new...
BioCryst is a commercial-stage biotech company that is committed to delivering extraordinary medicines that help patients live ordinary lives. We are passionate about advancing novel therapeutics for patients with rare and serious diseases. Our US headquarters is located in Durham, North Carolina, our European headquarters in Dublin, Ireland and our Discovery Center of Excellence in Birmingham, Alabama. With expertise in drug...
LGC is a leading, global life science tools company, providing mission-critical components and solutions into high-growth application areas across the human healthcare and applied market segments. Its high quality product portfolio is comprised of mission-critical tools for genomic analysis and for quality assurance applications, which are typically embedded and recurring within our customers’ products and workflows and are valued for...
LGC's Top Stability & Growth Strengths
Strong Market Position & Advantage: Holding the UK’s National Measurement Laboratory designation and Government Chemist role, plus leading positions in reference materials, proficiency testing, and agrigenomics/genotyping, reinforces defensible niche leadership. Acquisitions and widespread adoption of technologies like KASP genotyping underscore recognized authority in core segments.
Strong Revenue Growth: Reported revenue increased year over year in FY25, reversing the prior year’s dip. Adjusted EBITDA also rose, indicating improved top-line momentum alongside better operating results.
Future-Ready Strategy: Large-scale site expansions (Toronto, Guildford, Berlin) and integration of recent acquisitions point to capacity build-out and a scale-focused operating model. A new CEO, business-unit consolidation, and an Innovation Hub signal intent to sustain growth through portfolio development and execution.
Sartorius is a leading international partner of life sciences research and biopharmaceutical manufacturing. We help our customers #SimplifyProgress from drug discovery to manufacturing so that more people can have access to better medicine. With this, we are #PartOfTheSolution in the fight against diseases worldwide. With innovative laboratory instruments and consumables, the our Lab Products & Services division focuses on laboratories performing...
Sartorius's Top Stability & Growth Strengths
Strong Market Position & Advantage: Independent market analyses repeatedly characterize Sartorius as a top‑tier leader in single‑use bioprocessing, particularly in single‑use bioreactors, bags/assemblies, and integrated upstream platforms. Broad scale from bench to 2,000‑L, a large installed base, and continued capacity expansions reinforce this position.
Strong Revenue Growth: Company disclosures indicate sales grew 7.6% in constant currencies in 2025 to about €3.54 billion, with Q1 2026 up 7.5% and full‑year 2026 guidance of 5–9% growth. Order intake recovery from late 2024 and momentum in Bioprocess Solutions underpin this trend.
Profitability: Underlying EBITDA increased faster than sales in 2025, with margin near 30%, and management expects robust margins into 2026. Improving cash generation and recurring consumables contribute to sustained profitability.
Through pioneering life science and artificial intelligence, we developed our unique Nuritas MagnifierNπΦ platform that allows us to identify, unlock, clinically test and patent peptides; turning them into powerful and precise ingredients that elevate natural efficacy. We want to empower people to live healthier lives, naturally by making our everyday products healthier, safer, greener and more efficacious. From what we eat,...
Founded in 1996, PSC Biotech Corporation was created with the vision of providing life science companies unmatched support. To date, PSC Biotech Corporation now serves 1000 clients in more than 35 countries worldwide through professional services consulting, cloud-based software solutions, pharmaceuticals contract manufacturing, life science investment consulting, and metrology services. PSC Biotech Corporation has six unique divisions within the parent company...
Our Vision is to bring an Insect Farming revolution to the world, to end the overexploitation of land and ocean and to ultimately add to the progress of the human race. With revolutionary breeding and bio-conversion technologies, we maximise the extraction of high-value protein and oil products for the aquaculture, animal feed and plant nutrition industries. Our process produces no...
For 130 years, Merck, known as MSD outside of the United States and Canada, has been inventing for life, bringing forward medicines and vaccines for many of the world’s most challenging diseases in pursuit of our mission to save and improve lives. We demonstrate our commitment to patients and population health by increasing access to health care through far-reaching policies,...
Merck's Top Stability & Growth Strengths
Strong Market Position & Advantage: Merck holds a clear leadership position, anchored by Keytruda—the world’s top‑selling cancer medicine at $31.7B in 2025—and strong standings in vaccines and overall scale among global pharmas. Animal health also ranks among top players, reinforcing breadth across key healthcare markets.
Innovation-Driven Growth: A broad late‑stage pipeline and scientific presence (100+ ASCO 2026 abstracts across 25+ tumor types) span oncology, vaccines, infectious disease, and cardiometabolic areas. Ongoing label expansions and new formats like subcutaneous Keytruda (including U.S. Keytruda Qlex) are adding growth vectors.
Diversified Revenue Streams: Sales draw from oncology, vaccines (e.g., Gardasil over $10.7B in 2025), hospital acute care, and a growing animal health segment. Newer launches and alliances (e.g., Winrevair, IDVYNSO, and partnered oncology assets) are contributing to mix.
Our commitment to The Science of Healthier Animals® guides our work. We offer our customers a range of technology solutions which fuse DNA and DATA intelligence to deliver unparalleled animal lifecycle knowledge and uniquely insightful connections. Together we can shape a better future for animal well-being and food trust
.png)
Ancestry is the global leader in family history and consumer genomics. Every day, around the world, we help curious people like you embark on journeys of personal discovery to enrich lives. With our unparalleled collection of more than 40 billion records from more than 80 countries and 23+ million people in our growing DNA network, Ancestry helps customers discover their family...
Ancestry's Top Stability & Growth Strengths
Strong Market Position & Advantage: Company communications and industry coverage consistently depict Ancestry as the category leader, citing tens of billions of records, millions of subscribers, and the world’s largest consumer DNA network. Blackstone’s 2020 acquisition and a weakened rival landscape (e.g., 23andMe’s 2025 bankruptcy) reinforce its durable leadership.
Product Line Growth: Content and features expanded with 243 new historical collections in 2025, the largest-ever ethnicity update, and the iMemories acquisition adding media digitization. AI-enabled processing accelerates turning archives into searchable data, signaling ongoing product and data-scale growth.
Market Expansion: The company launched services in Italy and the Netherlands in 2025 and reported strong subscriber scale alongside rising community uploads. A multiyear partnership with the U.S. National Archives supports continued content expansion that benefits multiple markets.
Avectas is accelerating the future of cell therapy with a flexible, easy-to-integrate delivery platform that manufactures healthier and more functional cells for patients. Excelling at complex editing and challenging cargo delivery, the Avectas non-viral delivery platform ensures the next generation of cell therapies can be realized. The Solupore non-viral delivery system enables the next generation of cell therapies through unparalleled...
Zymeworks (NASDAQ:ZYME) is a clinical-stage biopharmaceutical company dedicated to the development of next-generation multifunctional biotherapeutics. Zymeworks’ suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of highly differentiated product candidates. Zymeworks’ lead clinical candidate, zanidatamab, is a novel Azymetric™ HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials...
Cellix is dedicated to providing our customers with easy-to-use benchtop instruments for cell analysis, cell sorting and customised solutions for microfluidics. Cellix was spun-out from Trinity College Dublin in 2006 when we launched our VenaFlux and Microfluidic Solutions ranges. Over the years, we have expanded our product offerings supporting our customers in several therapeutic areas including thrombosis, oncology, atherosclerosis, inflammation,...
Prothena is a late-stage clinical biotechnology company with expertise in protein dysregulation and a diverse pipeline of novel investigational therapies for neurodegenerative and rare peripheral amyloid diseases. We are committed to developing novel and transformative medicines to create a better future for people in critical need of new treatment options. Our product portfolio is designed to make a significant...
MMS is an award-winning, global clinical research organization (CRO) that supports leading pharmaceutical and biotech companies as well as many smaller enterprises across our spectrum of services. Having completed more than 50 submissions for drug approval over the last 5 years, we remain a top choice for sponsors who are looking for innovation and demand high quality from their CRO...
